{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:55:18Z","timestamp":1784037318395,"version":"3.55.0"},"reference-count":66,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.3892\/br.2012.42","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T15:35:36Z","timestamp":1354203336000},"page":"177-184","source":"Crossref","is-referenced-by-count":201,"title":["TNF inhibitor therapy for rheumatoid arthritis"],"prefix":"10.3892","volume":"1","author":[{"given":"XIXI","family":"MA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHENGQIAN","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"key20180107142513_b1-br-01-02-0177","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10067-002-8285-4","article-title":"Alkaline phosphatase in rheumatoid arthritis patients: possible contribution of bone-type ALP to the raised activities of ALP in rheumatoid arthritis patients","volume":"21","author":"Nanke","year":"2002","journal-title":"Clin Rheumatol"},{"key":"key20180107142513_b2-br-01-02-0177","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard.61.11.994","article-title":"Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women\u2019s Health Study","volume":"61","author":"Mikuls","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b3-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","article-title":"Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial","volume":"70","author":"Kremer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b4-br-01-02-0177","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3899\/jrheum.080663","article-title":"Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA","volume":"36","author":"Keystone","year":"2009","journal-title":"J Rheumatol"},{"key":"key20180107142513_b5-br-01-02-0177","first-page":"1532","article-title":"Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability","volume":"31","author":"Baumgartner","year":"2004","journal-title":"J Rheumatol"},{"key":"key20180107142513_b6-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00296-009-1111-4","article-title":"A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Rheumatol Int"},{"key":"key20180107142513_b7-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b8-br-01-02-0177","first-page":"724","article-title":"Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis","volume":"30","author":"Gao","year":"2010","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"key20180107142513_b9-br-01-02-0177","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0149-2918(00)87984-9","article-title":"Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo","volume":"22","author":"Mathias","year":"2000","journal-title":"Clin Ther"},{"key":"key20180107142513_b10-br-01-02-0177","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b11-br-01-02-0177","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1074-7613(00)80588-9","article-title":"The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues","volume":"9","author":"F\u00fctterer","year":"1998","journal-title":"Immunity"},{"key":"key20180107142513_b12-br-01-02-0177","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3188","article-title":"Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study","volume":"12","author":"Visvanathan","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key20180107142513_b13-br-01-02-0177","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","article-title":"Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study","volume":"32","author":"Kleinert","year":"2012","journal-title":"Rheumatol Int"},{"key":"key20180107142513_b14-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b15-br-01-02-0177","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"key20180107142513_b16-br-01-02-0177","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St. Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b17-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b18-br-01-02-0177","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","article-title":"RISING study: Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study","volume":"19","author":"Takeuchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"key20180107142513_b19-br-01-02-0177","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/ar3058","article-title":"74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis","volume":"12","author":"Delabaye","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key20180107142513_b20-br-01-02-0177","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"key20180107142513_b21-br-01-02-0177","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b22-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b23-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1136\/ard.2008.094524","article-title":"Improvements in clinical response between 12 and 24 weeks in patients with-rheumatoid arthritis on etanercept therapy with or without methotrexate","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b24-br-01-02-0177","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/s10165-010-0324-4","article-title":"Japan Biological Agent Study Integrated Consortium. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial","volume":"20","author":"Kameda","year":"2010","journal-title":"Mod Rheumatol"},{"key":"key20180107142513_b25-br-01-02-0177","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/art.23141","article-title":"Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b26-br-01-02-0177","first-page":"1232","article-title":"Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"key":"key20180107142513_b27-br-01-02-0177","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/ard.2005.035709","article-title":"Patient-reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b28-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.23493","article-title":"Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b29-br-01-02-0177","first-page":"659","article-title":"Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study","volume":"33","author":"Johnsen","year":"2006","journal-title":"J Rheumatol"},{"key":"key20180107142513_b30-br-01-02-0177","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease-modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b31-br-01-02-0177","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"key20180107142513_b32-br-01-02-0177","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","author":"Kavanaugh","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b33-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b34-br-01-02-0177","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3899\/jrheum.100752","article-title":"Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"key":"key20180107142513_b35-br-01-02-0177","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/s10165-011-0516-6","article-title":"Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)","volume":"22","author":"Takeuchi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"key20180107142513_b36-br-01-02-0177","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.101161","article-title":"Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study","volume":"39","author":"Strand","year":"2012","journal-title":"J Rheumatol"},{"key":"key20180107142513_b37-br-01-02-0177","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b38-br-01-02-0177","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"key20180107142513_b39-br-01-02-0177","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b40-br-01-02-0177","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2626","article-title":"Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial","author":"Weinblatt","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b41-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3899\/jrheum.111195","article-title":"Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: Results from the GO-FORWARD Study","volume":"39","author":"Genovese","year":"2012","journal-title":"J Rheumatol"},{"key":"key20180107142513_b42-br-01-02-0177","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","article-title":"Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b43-br-01-02-0177","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b44-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key20180107142513_b45-br-01-02-0177","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b46-br-01-02-0177","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b47-br-01-02-0177","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b48-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"key20180107142513_b49-br-01-02-0177","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/art.30387","article-title":"Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b50-br-01-02-0177","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2008.102509","article-title":"Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial","volume":"69","author":"Kekow","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b51-br-01-02-0177","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"key20180107142513_b52-br-01-02-0177","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2474-12-261","article-title":"Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study","volume":"12","author":"Haraoui","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"key20180107142513_b53-br-01-02-0177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"key20180107142513_b54-br-01-02-0177","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":"Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"key20180107142513_b55-br-01-02-0177","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b56-br-01-02-0177","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20180107142513_b57-br-01-02-0177","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/S1516-31802010000500013","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","volume":"128","author":"Singh","year":"2010","journal-title":"Sao Paulo Med J"},{"key":"key20180107142513_b58-br-01-02-0177","first-page":"247","article-title":"Grupo de Estudos de Artrite Reumat\u00f3ide da Sociedade Portuguesa de Reumatologia. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience","volume":"31","author":"Fonseca","year":"2006","journal-title":"Acta Reumatol Port"},{"key":"key20180107142513_b59-br-01-02-0177","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b60-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/ard.2010.146365","article-title":"The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents","volume":"70","author":"Curtis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b61-br-01-02-0177","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180107142513_b62-br-01-02-0177","first-page":"1098","article-title":"The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis","volume":"31","author":"Hansen","year":"2004","journal-title":"J Rheumatol"},{"key":"key20180107142513_b63-br-01-02-0177","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20180107142513_b64-br-01-02-0177","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009740510026887","article-title":"Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital","volume":"34","author":"Wick","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"key20180107142513_b65-br-01-02-0177","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/rheumatology\/ken127","article-title":"Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug","volume":"47","author":"Hyrich","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"key20180107142513_b66-br-01-02-0177","first-page":"107","article-title":"Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature","volume":"61","author":"Scrivo","year":"2009","journal-title":"Reumatismo"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2012.42\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:29:28Z","timestamp":1745364568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2012.42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,11,29]]},"published-print":{"date-parts":[[2013]]}},"alternative-id":["10.3892\/br.2012.42"],"URL":"https:\/\/doi.org\/10.3892\/br.2012.42","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}